Small Molecular Weight Myc-max Inhibitors
Categories: “Cancer Therapeutics“
Reference #: 2007-026
OTC Contact: Ruchika Nijhara, Ph.D., MBA, CLP (Directory Information | Send a Message)
c-Myc is implicated in pathogenesis, evolution and/or survival of many human cancers and therapeutic targeting of this oncoprotein offers a great commercial potential. However, all the approaches so far to inhibit c-myc have not been successful. The present invention describes small molecular weight compounds to inhibit c-Myc function by abrogating the association between c-Myc and its binding partner, Max. Specifically, the invention embodies compounds and compositions and methods to inhibit growth or proliferation of the cell.
- High potency at low doses
- High efficacy
Stage of Development
Compounds show enhanced growth inhibition of c-Myc-expressing cells in a manner that generally correlates with their ability to disrupt c-Myc-Max association and DNA binding. Further, studies show that the compounds specifically target c-Myc.
“Improved low molecular weight Myc-Max inhibitor” Metallo et al; Mol Cancer Ther. 2007 Sep;6(9):2399-408.
US Patent Application # 11/707,421 and PCT application # PCT/US07/04039 entitled “Improved Low molecular weight Myc-Max Inhibitors, filed on February 16, 2007.